Comparative Effectiveness of Recombinant Zoster and Live Attenuated Zoster Vaccines in Chronic Inflammatory Skin Diseases: A Retrospective Cohort Study
Journal of Medical Virology · 2026
DOI: 10.1002/jmv.70893 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Cheryl Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Rice University, Houston, Texas, USA. Hauptthemen laut MEDLINE: Herpes Zoster Vaccine, Herpes Zoster, Vaccine Efficacy, Skin Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Yin Shu-Tien Foundation, Taipei Veterans General Hospital-National Yang Ming Chiao Tung University Excellent Physician Scientists Cultivation Program.
Abstract (Originalsprache)
Patients with chronic inflammatory skin diseases (CISDs) are at an elevated risk for herpes zoster (HZ) and its complications. Therefore, effective prevention strategies are crucial for this high‐risk population. This study aimed to compare the vaccine effectiveness of recombinant zoster vaccine (RZV) versus live attenuated vaccine (LAV) in patients with CISDs. A retrospective cohort study was performed using data from the U.S. Collaborative Network of TriNetX. Adults aged ≥ 18 years with CISDs between 2014 and 2020 were included. The primary outcome was incident HZ; secondary outcomes included ophthalmic zoster (OZ), postherpetic neuralgia (PHN), and complicated HZ. Propensity score matching was performed for head‐to‐head comparisons, and Cox proportional hazards models were used to estimate hazard ratios (HRs). Compared with LAV, patients receiving RZV had a significantly lower risk of HZ (two‐dose RZV: HR 0.61; 95% CI, 0.54–0.69; one‐dose RZV: HR 0.65; 95% CI, 0.58–0.75). RZV was also associated with reduced risks of OZ, PHN, and complicated HZ. Subgroup analyses showed consistent risk reduction across patients with psoriasis, atopic dermatitis, hidradenitis suppurativa, vitiligo, and pemphigoid, as well as among adults aged ≥ 65 years. RZV is more effective than LAV in preventing HZ and its complications such as ophthalmic zoster and postherpetic neuralgia among patients with CISDs. These findings provide real‐world evidence that prioritize RZV use in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rice University, Houston, Texas, USA.
- Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan.
- Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Institute of Public Health and Department of Public Health, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
- Department of Dermatology, National Yang Ming Chiao Tung University, Taipei, Taiwan.
ORCID-Profile: Cheryl Lee, Sheng-Hsiang Ma, Tai-Li Chen
Förderung
- Yin Shu-Tien Foundation, Taipei Veterans General Hospital-National Yang Ming Chiao Tung University Excellent Physician Scientists Cultivation Program
Zitieren
APA
Lee, C., Ma, S. H., Ou, W. F., Wu, C. Y., Chen, C. C., & Chen, T. L. (2026). Comparative Effectiveness of Recombinant Zoster and Live Attenuated Zoster Vaccines in Chronic Inflammatory Skin Diseases: A Retrospective Cohort Study. Journal of Medical Virology. https://doi.org/10.1002/jmv.70893
Vancouver
Lee C, Ma SH, Ou WF, Wu CY, Chen CC, Chen TL. Comparative Effectiveness of Recombinant Zoster and Live Attenuated Zoster Vaccines in Chronic Inflammatory Skin Diseases: A Retrospective Cohort Study. Journal of Medical Virology. 2026. doi:10.1002/jmv.70893
BibTeX
@article{Lee2026,
author = {Lee, Cheryl and Ma, Sheng-Hsiang and Ou, Wei-Fan and Wu, Chen-Yi and Chen, Chih-Chiang and Chen, Tai-Li},
title = {Comparative Effectiveness of Recombinant Zoster and Live Attenuated Zoster Vaccines in Chronic Inflammatory Skin Diseases: A Retrospective Cohort Study},
journal = {Journal of Medical Virology},
year = {2026},
doi = {10.1002/jmv.70893}
}
EUVIMED